Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T3512 | S49076 HCl | 1265966-31-1 |
|
|
S49076 HCl (S-49076 Hydrochloride) is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 HCl potently blocked cellular phosphorylation of MET, AXL, an... | ||||
T78206 | Canlitinib | 2222730-78-9 | 98% |
|
Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research. | ||||
T78843 | MET/PDGFRA-IN-1 | 98% |
|
|
MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET. It impedes MET phosphorylation, thereby... | ||||
T78844 | MET/PDGFRA-IN-2 | 98% |
|
|
MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positive cell... | ||||
T78934 | C-Met-IN-18 | 98% |
|
|
C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively. I... | ||||
T79142 | C-Met-IN-17 | 98% |
|
|
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1] | ||||
T79466 | Antitumor agent-111 | 98% |
|
|
Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects. It impedes the cell cycle at t... | ||||
T79612 | Tyrosine kinase-IN-6 | 2377507-01-0 | 98% |
|
Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1]. | ||||
T79715 | C-Met-IN-19 | 98% |
|
|
c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549, H... | ||||
T80521 | Caveolin-1 (82-101) amide (human, mouse, rat) | 2757108-69-1 | 98% |
|
Caveolin-1 (82-101) amide (human, mouse, rat), also known as Caveolin-1 scaffolding domain peptide, mitigates aging-related detrimental alterations in various or... | ||||
T82608 | Davutamig | 2648058-48-2 | 98% |
Davutamig
|
Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor. It functio... | ||||
T83433 | 1D228 | 98% |
|
|
1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration of cance... | ||||
T12417 | PF-04217903 methanesulfonate | 956906-93-7 | 98% |
|
PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met). | ||||
T10653 | C-met-IN-1 | 2084836-84-8 | 98% |
|
c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity. | ||||
T17184 | Tyrosine kinase inhibitor | 1021950-26-4 | 98% |
|
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents. | ||||
T15383 | Glesatinib hydrochloride | 1123838-51-6 | 98% |
|
Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P... | ||||
T10654 | C-Met-IN-2 | 1635406-73-3 | 98% |
|
c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity. | ||||
T12418 | PF-04217903 phenolsulfonate | 1159490-85-3 | 98% |
|
PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met). | ||||
T15384 | Glesatinib | 936694-12-1 | 98% |
|
Glesatinib is an orally active and potent dual inhibitor of MET/SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multi... | ||||
TN4474 | Macrocarpal B | 142698-60-0 | 98% |
|
The intestinal absorption of M-A, Macrocarpal B, and Cy-C was passive diffusion as the dominating process and Cy-C was partly ATP-dependent. |